Clinical Trials | May 14, 2026
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure
Shashwat Goenka takes over as Vice President of industry body
The medical-grade Angelas diode laser calibrated at a 1470 nm wavelength supports microsurgeries across multiple specialties
Subscribe To Our Newsletter & Stay Updated
